Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition

Journal of Hematology and Oncology

Volumn 6, Issue 1, 2013, Pages

  Falcon, Beverly L ^a   O'Clair, Belinda ^b   McClure, Don ^a   Evans, Glenn F ^a   Stewart, Julie ^a   Swearingen, Michelle L ^a   Chen, Yuefeng ^a   Allard, Kevin ^b   Lee, Linda N ^a   Neote, Kuldeep ^a   McEwen, Dyke P ^b   Uhlik, Mark T ^a   Chintharlapalli, Sudhakar ^a  

^a ELI LILLY AND COMPANY   (United States)

^b Essen BioScience Inc   (United States)

Author keywords

Adipose derived stem cells (ADSC); Angiogenesis; Endothelial colony forming cells (ECFC); Vascular endothelial growth factor (VEGF)

Indexed keywords

BEVACIZUMAB; COMBRETASTATIN; FIBROBLAST GROWTH FACTOR 2; RAMUCIRUMAB; SURAMIN; VASCULOTROPIN;

ADIPOSE TISSUE CELL; ANGIOGENESIS; ARTICLE; BLOOD VESSEL; COCULTURE; CONTROLLED STUDY; DRUG TARGETING; ENDOTHELIUM CELL; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IN VITRO STUDY; INHIBITION KINETICS; PERFUSION; SIGNAL TRANSDUCTION; STEM CELL; UMBILICAL CORD BLOOD; VASCULARIZATION;

ADIPOCYTES; ANGIOGENESIS INHIBITORS; ANIMALS; COCULTURE TECHNIQUES; FEMALE; FIBROBLASTS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MICE; MICE, NUDE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NEOVASCULARIZATION, PHYSIOLOGIC; STEM CELLS; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84876682004     PISSN: None     EISSN: 17568722     Source Type: Journal    
DOI: 10.1186/1756-8722-6-31     Document Type: Article

References (52)

1. Potent VEGF blockade causes regression of coopted vessels in a model of neuroblastoma. Kim ES, Serur A, Huang J, Manley CA, McCrudden KW, Frischer JS, Soffer SZ, Ring L, New T, Zabski S, Proc Natl Acad Sci U S A 2002 99 11399 11404 10.1073/pnas.172398399 12177446 (Pubitemid 34920937)
2. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors. Prewett M, Huber J, Li Y, Santiago A, O'Connor W, King K, Overholser J, Hooper A, Pytowski B, Witte L, Cancer Res 1999 59 5209 5218 10537299 (Pubitemid 29503984)
3. VEGF-targeted therapy: mechanisms of anti-tumour activity. Ellis LM, Hicklin DJ, Nat Rev Cancer 2008 8 579 591 10.1038/nrc2403 18596824
4. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Casanovas O, Hicklin DJ, Bergers G, Hanahan D, Cancer Cell 2005 8 299 309 10.1016/j.ccr.2005.09.005 16226705 (Pubitemid 41443415)
5. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Ebos JM, Lee CR, Cruz-Munoz W, Bjarnason GA, Christensen JG, Kerbel RS, Cancer Cell 2009 15 232 239 10.1016/j.ccr.2009.01.021 19249681
6. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Paez-Ribes M, Allen E, Hudock J, Takeda T, Okuyama H, Vinals F, Inoue M, Bergers G, Hanahan D, Casanovas O, Cancer Cell 2009 15 220 231 10.1016/j.ccr.2009.01.027 19249680
7. Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients. Griffioen AW, Mans LA, de Graaf AM, Nowak-Sliwinska P, de Hoog CL, de Jong TA, Vyth-Dreese FA, van Beijnum JR, Bex A, Jonasch E, Clin Cancer Res 2012 18 3961 3971 10.1158/1078-0432.CCR-12-0002 22573349
8. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Inai T, Mancuso M, Hashizume H, Baffert F, Haskell A, Baluk P, Hu-Lowe DD, Shalinsky DR, Thurston G, Yancopoulos GD, McDonald DM, Am J Pathol 2004 165 35 52 10.1016/S0002-9440(10)63273-7 15215160 (Pubitemid 38821812)
9. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Cancer Cell 2007 11 83 95 10.1016/j.ccr.2006.11.021 17222792 (Pubitemid 46075199)
10. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Winkler F, Kozin SV, Tong RT, Chae SS, Booth MF, Garkavtsev I, Xu L, Hicklin DJ, Fukumura D, di Tomaso E, Cancer Cell 2004 6 553 563 15607960 (Pubitemid 40017699)
11. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. Benjamin LE, Golijanin D, Itin A, Pode D, Keshet E, J Clin Invest 1999 103 159 165 10.1172/JCI5028 9916127 (Pubitemid 29053133)
12. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Benjamin LE, Hemo I, Keshet E, Development 1998 125 1591 1598 9521897 (Pubitemid 28256727)
13. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. Bergers G, Song S, Meyer-Morse N, Bergsland E, Hanahan D, J Clin Invest 2003 111 1287 1295 12727920 (Pubitemid 36554699)
14. Modes of resistance to anti-angiogenic therapy. Bergers G, Hanahan D, Nat Rev Cancer 2008 8 592 603 10.1038/nrc2442 18650835
15. Upregulated stromal EGFR and vascular remodeling in mouse xenograft models of angiogenesis inhibitor-resistant human lung adenocarcinoma. Cascone T, Herynk MH, Xu L, Du Z, Kadara H, Nilsson MB, Oborn CJ, Park YY, Erez B, Jacoby JJ, J Clin Invest 2011 121 1313 1328 10.1172/JCI42405 21436589
16. Hypoxia inducible factor-1alpha is necessary for invasive phenotype in Vegf-deleted islet cell tumors. Takeda T, Okuyama H, Nishizawa Y, Tomita S, Inoue M, Sci Rep 2012 2 494 22768384
17. Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Jain RK, Science 2005 307 58 62 10.1126/science.1104819 15637262 (Pubitemid 40093472)
18. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Tong RT, Boucher Y, Kozin SV, Winkler F, Hicklin DJ, Jain RK, Cancer Res 2004 64 3731 3736 10.1158/0008-5472.CAN-04-0074 15172975 (Pubitemid 38697278)
19. Heterogeneity of the tumor vasculature. Nagy JA, Chang SH, Shih SC, Dvorak AM, Dvorak HF, Semin Thromb Hemost 2010 36 321 331 10.1055/s-0030-1253454 20490982
20. Heterogeneity of the tumor vasculature: the need for new tumor blood vessel type-specific targets. Nagy JA, Dvorak HF, Clin Exp Metastasis 2012 29 657 662 10.1007/s10585-012-9500-6 22692562
21. Tumor-surrogate blood vessel subtypes exhibit differential susceptibility to anti-VEGF therapy. Sitohy B, Nagy JA, Jaminet SC, Dvorak HF, Cancer Res 2011 71 7021 7028 10.1158/0008-5472.CAN-11-1693 21937680
22. Adipose tissue progenitor cells directly interact with endothelial cells to induce vascular network formation. Merfeld-Clauss S, Gollahalli N, March KL, Traktuev DO, Tissue Eng Part A 2010 16 2953 2966 10.1089/ten.tea.2009.0635 20486792
23. Imaged-based high-throughput screening for anti-angiogenic drug discovery. Evensen L, Link W, Lorens JB, Curr Pharm Des 2010 16 3958 3963 10.2174/138161210794455030 21158729
24. A novel imaging-based high-throughput screening approach to anti-angiogenic drug discovery. Evensen L, Micklem DR, Link W, Lorens JB, Cytometry A 2010 77 41 51 19834964
25. Characterization of a novel angiogenic model based on stable, fluorescently labelled endothelial cell lines amenable to scale-up for high content screening. Prigozhina NL, Heisel A, Wei K, Noberini R, Hunter EA, Calzolari D, Seldeen JR, Pasquale EB, Ruiz-Lozano P, Mercola M, Price JH, Biol Cell 2011 103 467 481 10.1042/BC20100146 21732911
26. Uses of the in vitro endothelial-fibroblast organotypic co-culture assay in angiogenesis research. Hetheridge C, Mavria G, Mellor H, Biochem Soc Trans 2011 39 1597 1600 10.1042/BST20110738 22103493
27. Contrasting actions of selective inhibitors of angiopoietin-1 and angiopoietin-2 on the normalization of tumor blood vessels. Falcon BL, Hashizume H, Koumoutsakos P, Chou J, Bready JV, Coxon A, Oliner JD, McDonald DM, Am J Pathol 2009 175 2159 2170 10.2353/ajpath.2009.090391 19815705
28. Sequential loss of tumor vessel pericytes and endothelial cells after inhibition of platelet-derived growth factor B by selective aptamer AX102. Sennino B, Falcon BL, McCauley D, Le T, McCauley T, Kurz JC, Haskell A, Epstein DM, McDonald DM, Cancer Res 2007 67 7358 7367 10.1158/0008-5472.CAN-07-0293 17671206 (Pubitemid 47206566)
29. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. You WK, Sennino B, Williamson CW, Falcon B, Hashizume H, Yao LC, Aftab DT, McDonald DM, Cancer Res 2011 71 4758 4768 10.1158/0008-5472.CAN-10- 2527 21613405
30. Endothelial/pericyte interactions. Armulik A, Abramsson A, Betsholtz C, Circ Res 2005 97 512 523 10.1161/01.RES.0000182903.16652.d7 16166562 (Pubitemid 41361741)
31. Role of pericytes in vascular morphogenesis. Betsholtz C, Lindblom P, Gerhardt H, EXS 2005 94 115 125 15617474
32. Endothelium-specific platelet-derived growth factor-B ablation mimics diabetic retinopathy. Enge M, Bjarnegard M, Gerhardt H, Gustafsson E, Kalen M, Asker N, Hammes HP, Shani M, Fassler R, Betsholtz C, EMBO J 2002 21 4307 4316 10.1093/emboj/cdf418 12169633
33. Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody. Shen J, Vil MD, Prewett M, Damoci C, Zhang H, Li H, Jimenez X, Deevi DS, Iacolina M, Kayas A, Neoplasia 2009 11 594 604 19484148
34. DLL4-Notch signaling mediates tumor resistance to anti-VEGF therapy in vivo. Li JL, Sainson RC, Oon CE, Turley H, Leek R, Sheldon H, Bridges E, Shi W, Snell C, Bowden ET, Cancer Res 2011 71 6073 6083 10.1158/0008-5472.CAN-11-1704 21803743
35. Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo-6, 7-di hydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575). Lanz TA, Hosley JD, Adams WJ, Merchant KM, J Pharmacol Exp Ther 2004 309 49 55 10.1124/jpet.103.060715 14718585 (Pubitemid 38393113)
36. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. Wong GT, Manfra D, Poulet FM, Zhang Q, Josien H, Bara T, Engstrom L, Pinzon-Ortiz M, Fine JS, Lee HJ, J Biol Chem 2004 279 12876 12882 14709552 (Pubitemid 38445862)
37. An in vitro model of angiogenesis: basic features. Bishop ET, Bell GT, Bloor S, Broom IJ, Hendry NF, Wheatley DN, Angiogenesis 1999 3 335 344 10.1023/A:1026546219962 14517413 (Pubitemid 129643976)
38. Developing and applying a gene functional association network for anti-angiogenic kinase inhibitor activity assessment in an angiogenesis co-culture model. Chen Y, Wei T, Yan L, Lawrence F, Qian HR, Burkholder TP, Starling JJ, Yingling JM, Shou J, BMC Genomics 2008 9 264 10.1186/1471-2164-9- 264 18518970 (Pubitemid 351895450)
39. Comparison of three in vitro human 'angiogenesis' assays with capillaries formed in vivo. Donovan D, Brown NJ, Bishop ET, Lewis CE, Angiogenesis 2001 4 113 121 10.1023/A:1012218401036 11806243 (Pubitemid 34032697)
40. Blockade of Dll4 inhibits tumour growth by promoting non-productive angiogenesis. Noguera-Troise I, Daly C, Papadopoulos NJ, Coetzee S, Boland P, Gale NW, Lin HC, Yancopoulos GD, Thurston G, Nature 2006 444 1032 1037 10.1038/nature05355 17183313 (Pubitemid 46018516)
41. Inhibition of Dll4 signalling inhibits tumour growth by deregulating angiogenesis. Ridgway J, Zhang G, Wu Y, Stawicki S, Liang WC, Chanthery Y, Kowalski J, Watts RJ, Callahan C, Kasman I, Nature 2006 444 1083 1087 10.1038/nature05313 17183323 (Pubitemid 46018529)
42. Mural cell associated VEGF is required for organotypic vessel formation. Evensen L, Micklem DR, Blois A, Berge SV, Aarsaether N, Littlewood-Evans A, Wood J, Lorens JB, PLoS One 2009 4 5798 10.1371/journal.pone.0005798 19495422
43. Autocrine VEGF signaling is required for vascular homeostasis. Lee S, Chen TT, Barber CL, Jordan MC, Murdock J, Desai S, Ferrara N, Nagy A, Roos KP, Iruela-Arispe ML, Cell 2007 130 691 703 10.1016/j.cell.2007.06.054 17719546 (Pubitemid 47268059)
44. VEGF receptor signalling-in control of vascular function. Olsson AK, Dimberg A, Kreuger J, Claesson-Welsh L, Nat Rev Mol Cell Biol 2006 7 359 371 10.1038/nrm1911 16633338
45. Combretastatin A4 phosphate induces rapid regression of tumor neovessels and growth through interference with vascular endothelial-cadherin signaling. Vincent L, Kermani P, Young LM, Cheng J, Zhang F, Shido K, Lam G, Bompais-Vincent H, Zhu Z, Hicklin DJ, J Clin Invest 2005 115 2992 3006 10.1172/JCI24586 16224539 (Pubitemid 41567565)
46. Retinoblastoma tumor vessel maturation impacts efficacy of vessel targeting in the LH(BETA)T(AG) mouse model. Jockovich ME, Bajenaru ML, Pina Y, Suarez F, Feuer W, Fini ME, Murray TG, Invest Ophthalmol Vis Sci 2007 48 2476 2482 10.1167/iovs.06-1397 17525173 (Pubitemid 351261194)
47. Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancer. Nathan P, Zweifel M, Padhani AR, Koh DM, Ng M, Collins DJ, Harris A, Carden C, Smythe J, Fisher N, Clin Cancer Res 2012 18 3428 3439 10.1158/1078-0432.CCR-11-3376 22645052
48. Dual targeting of tumor vasculature: combining Avastin and vascular disrupting agents (CA4P or OXi4503). Siemann DW, Shi W, Anticancer Res 2008 28 2027 2031 18751370
49. Modern phenotypic drug discovery is a viable, neoclassic pharma strategy. Lee JA, Uhlik MT, Moxham CM, Tomandl D, Sall DJ, J Med Chem 2012 55 4527 4538 10.1021/jm201649s 22409666
50. Tasisulam sodium, an antitumor agent that inhibits mitotic progression and induces vascular normalization. Meier T, Uhlik M, Chintharlapalli S, Dowless M, Van Horn R, Stewart J, Blosser W, Cook J, Young D, Ye X, Mol Cancer Ther 2011 10 2168 2178 10.1158/1535-7163.MCT-11-0323 21903607
51. Chapter 13. An in vivo experimental model for postnatal vasculogenesis. Melero-Martin JM, Bischoff J, Methods Enzymol 2008 445 303 329 19022065
52. B.L. Falcon, J. Stewart, S. Ezell, J. Hanson, Wijsman J.High-content multiplexed tissue imaging and quantification for cancer drug discovery Drug Discov Today 2012 Epub ahead of print